Compare · LUNG vs MMM
LUNG vs MMM
Side-by-side comparison of Pulmonx Corporation (LUNG) and 3M Company (MMM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LUNG and MMM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MMM is the larger of the two at $82.16B, about 1263.1x LUNG ($65.0M).
- Over the past year, LUNG is down 42.6% and MMM is down 0.4% - MMM leads by 42.3 points.
- MMM has hit the wire 7 times in the past 4 weeks while LUNG has been quiet.
- MMM has more recent analyst coverage (25 ratings vs 17 for LUNG).
- Company
- Pulmonx Corporation
- 3M Company
- Price
- $1.54+5.48%
- $157.46+1.39%
- Market cap
- $65.0M
- $82.16B
- 1M return
- +1.32%
- +0.69%
- 1Y return
- -42.64%
- -0.38%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 0
- 7
- Recent ratings
- 17
- 25
Pulmonx Corporation
Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
3M Company
3M Company develops, manufactures, and markets various products worldwide. It operates through four business segments: Safety and Industrial, Transportation and Electronics, Health Care, and Consumer. The Safety and Industrial segment offers personal safety products, industrial adhesives and tapes, abrasives, closure and masking systems, electrical markets, automotive aftermarket, and roofing granules to industrial, electrical, and safety markets. The Transportation and Electronics provides electronics, such as display materials and systems, electronic materials solutions; automotive and aerospace, and commercial solutions; advanced materials; and transportation safety products to transportation and electronic original equipment manufacturer customers. The Health Care segment offers medical and surgical supplies, skin health and infection prevention products, oral care, separation and purification sciences, health information systems, drug delivery systems, and food safety products to healthcare industry. The Consumer segment provides home improvement, home care, and consumer health care products, as well as stationery and office supplies to various consumers. This segment is also involved in the retail auto care business. It offers its products through various e-commerce and traditional wholesalers, retailers, jobbers, distributors, and dealers, as well as directly to users. 3M Company has a strategic collaboration with Merry Maids in residential cleaning sector; and collaborations with The Infectious Disease Research Institute and Duke Human Vaccine Institute to create a vaccine candidate with potential to provide protection against multiple variants of SARS-CoV-2. The company was founded in 1902 and is headquartered in St. Paul, Minnesota.
Latest LUNG
- Director Burns Thomas William was granted 40,000 shares, increasing direct ownership by 54% to 113,399 units (SEC Form 4)
- Director Ferrari Richard was granted 40,000 shares, increasing direct ownership by 46% to 127,024 units (SEC Form 4)
- Director Florin Daniel P was granted 40,000 shares, increasing direct ownership by 43% to 133,910 units (SEC Form 4)
- Director Melenikiotou Georgia was granted 40,000 shares, increasing direct ownership by 40% to 139,714 units (SEC Form 4)
- Director Sullivan Tiffany was granted 40,000 shares, increasing direct ownership by 53% to 115,199 units (SEC Form 4)
- Director Mead Dana G Jr. was granted 40,000 shares, increasing direct ownership by 40% to 139,714 units (SEC Form 4)
- Pulmonx Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Chief Science &Techn. Officer Radhakrishnan Srikanth sold $22,325 worth of shares (14,497 units at $1.54), decreasing direct ownership by 4% to 331,239 units (SEC Form 4) to cover withholding tax
- GENERAL COUNSEL Lehman David Aaron sold $22,475 worth of shares (14,594 units at $1.54), decreasing direct ownership by 4% to 376,161 units (SEC Form 4) (withholding obligation)
- CHIEF COMMERCIAL OFFICER Rose Geoffrey Beran sold $12,355 worth of shares (8,023 units at $1.54), decreasing direct ownership by 2% to 457,711 units (SEC Form 4) (for withholding tax)
Latest MMM
- 3M Announces Upcoming Investor Event
- 3M Young Scientist Challenge Names 10 Finalists for 2026 National Competition
- Group President Bauer Wendy A exercised 7,952 shares at a strike of $159.96 and covered exercise/tax liability with 3,558 shares, increasing direct ownership by 94% to 9,086 units (SEC Form 4)
- 3M and Discovery Education announce 37 State Merit Winners and four Honorable Mentions in 2026 3M Young Scientist Challenge
- 3M joins Cadillac Formula 1® Team as Official Material Science Partner to accelerate racing performance
- 3M and Airbus announce agreement to advance A220 passenger comfort and aircraft performance through advanced insulation technology
- 3M launches Ask 3M, an AI-powered tool for faster access to technical expertise
- Goldman resumed coverage on 3M with a new price target
- Bernstein initiated coverage on 3M with a new price target
- Director Rumsey Jennifer was granted 1,196 shares (SEC Form 4)